Early onset macular drusen and C3 glomerulopathy (formerly type II membranoproliferative glomerulonephritis-associated drusen)
"I don't have any problems with my vision, but my optometrist saw changes in my retina that I want a diagnosis for."
History of Present Illness
The patient is a 32-year-old female who was noted to have macular changes in the absence of visual changes on a routine exam by an optometrist. She was recommended to begin Age-Related Eye Disease Study (AREDS) formulation vitamins and told to follow up with an ophthalmologist at her next annual exam. The ophthalmologist described early-onset age-related macular degeneration (AMD) without visual changes, and the patient was referred to the University of Iowa.
At her evaluation at the University of Iowa, she did not report any visual problems, including no decreased visual acuity, night blindness, metamorphopsia, scotomata, photophobia, pain, flashes, nor floaters.
Past Ocular History
- Myopia and spectacle wear
Past Medical History
End-stage renal disease, atopic rhinitis, degeneration of intervertebral lumbar disc, Hashimoto thyroiditis, obesity, anxiety, and depression
- 81 mg/day aspirin
- 5 mg/day buspirone
- 10 mg/day cetirizine
- 10 mg/day cyclobenzaprine
- 25 mg/day hydrochlorothiazide
- 112 mcg/day levothyroxine
- 15 mg/day meloxicam
- 10 mg/day montelukast
- 500 mg/day naproxen
- 20 mg/day omeprazole
- 80 mg/day propranolol
- daily multivitamin
Family history is notable for a maternal grandmother with AMD. She did not know at what age her grandmother presented with signs of AMD. No other known affected family members, including her four children, and no known family history of renal disease.
Non-smoker, otherwise non-contributory.
Review of Systems
Positive for history of kidney disease. Otherwise negative except for what is detailed in the history of present illness.
By Snellen acuity chart
- Right eye (OD): 20/15 with correction
- Left eye (OS): 20/15 with correction
Intraocular Pressure (IOP)
- OD: 20 mmHg by Tonopen®
- OS: 18 mmHg by Tonopen®
- OD: 5 mm in dark, 3 mm in light, no relative afferent pupillary defect (RAPD)
- OS: 5 mm in dark, 3 mm in light, no RAPD
Confrontation visual fields
- Full to confrontation – count fingers
Slit lamp exam
- Lids/lashes:Normal, both eyes
- Conjunctiva/sclera: Normal, both eyes
- Cornea: Clear, both eyes
- Anterior chamber: Deep and quiet, both eyes
- Iris: Normal architecture, both eyes
- Lens: Clear, both eyes
Dilated fundus examination (DFE)
- Vitreous:Clear, both eyes
- Disc: Normal and perfused, both eyes
- Cup-to-disc ratio: 0.2, both eyes
- Maculae: There were multiple small to medium sized, round, yellow drusen, some confluent in the macula and nasal to the nerve in both eyes. There was more clustering of drusen in the temporal macula. A few drusen were near, but not completely abutting the optic nerve.
- Vessels: Normal, both eyes
- Periphery: Normal, both eyes
- Age-related macular degeneration (related case | related tutorial)
- Glomerulopathy-associated drusen (including C3 glomerulopathies)
- Pattern macular dystrophy (PRPH2 mutation, ABCA4 mutation)
- Autosomal dominant radial drusen (a.k.a. familial dominant drusen, Malattia Leventinese, Doyne honeycomb retinal dystrophy due to EFEMP-1/fibulin-3 mutation)
- North Carolina macular dystrophy (PRDM13 mutation)
- Sorsby macular dystrophy (TIMP3 mutation)
- Cuticular drusen
The patient remained visually asymptomatic, and she continued to monitor her kidney function regularly with her nephrologist. After careful counseling of the limited data on the treatment and prognosis for drusen in patients without AMD, she decided to restart her AREDS vitamins. She focused her efforts on minimizing her risk factors, including control of blood pressure, weight, diet, and avoidance of smoking. Additionally, she was provided an Amsler grid to monitor for new visual symptoms. Due to her distance from the University of Iowa, the patient decided to follow locally and only return if she developed visual symptoms.
She returned to clinic two years later with new shadows and glare in the left eye greater than the right, which began after a recent transient ischemic attack. She also had a new diagnosis of antiphospholipid antibody syndrome. No ocular structural cause was identified and her drusen remained stable without complications.
Glomerulopathy-associated drusen (formerly type II membranoproliferative glomerulonephritis-associated drusen)
The classification of glomerulopathy has recently undergone changes, and the literature is beginning to adopt new terminology. Previously, the underlying kidney disease associated with drusen in the retina was called type II membranoproliferative glomerulonephritis (MPGN). With new understanding of the disease, the underlying kidney disease that included MPGN has been reclassified to C3 glomerulopathies with subgroups named dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Both DDD and C3GN fall under complement-mediated disease, as compared to immune complex-mediated disease. The associated retinal disease has less consensus of terminology and is referred to as glomerulopathy-associated drusen, glomerulonephritis-associated drusen, early-onset drusen, or basal laminar drusen.
C3 glomerulopathies are rare disorders. The female-to-male ratio for kidney disease is 1:1 and retinal disease is 2.7:1 to 1:1.5.[3-5] The mean age of onset for kidney disease is age 30±19 for C3GN and 19±18 for DDD. Retinal changes have an early onset with the average age of 41±21 years in one series and as early as the teenage years in another.[4 ,6]
The major derangement in C3 glomerulopathy and the associated retinal disease is the alternative complement pathway. The most common mutation is in complement factor H (CFH, chromosome 1q32-q32.1), but other complement pathway genes have been associated with the disease including CFI, MCP, CFB, and CFHR5. These mutations are often loss of function of the complement inhibitors and thus leads to increased activity of the complement cascade.
CFH plays an integral role as a protein in the alternative complement pathway, and it acts to bind C3b and increase the breakdown of the C3bBb convertase.[4 ,7] CFH also functions as a complement factor I (CFI) cofactor, which also inhibits C3b. CFH mutations have been associated with a number of diseases including Alzheimer disease, age-related macular degeneration, C3 glomerulopathies, cuticular drusen, and meningococcal disease susceptibility.[7 ,8] For example, the Y402H mutation of CFH is associated with a 3-fold increased risk for age-related macular degeneration. This Y402H variant of CFH shows an even higher association in those with cuticular drusen. Another macular disorder that presents with drusen, autosomal dominant radial drusen, is not associated with CFH mutations. In glomerulopathy-associated drusen, a molecular diagnosis is not always available in published studies, but a CFH mutation was found in all patients with molecular data available in one study.
Both the eye (i.e. choriocapillaris/Bruch's membrane/retinal pigment epithelium interface) and the kidney (i.e. capillary tuft/glomerular basement membrane epithelial interface) lack the membrane bound regulators of the complement cascade, indicating that both are likely affected by a common disease process.[4 ,9] Without these regulators, the inappropriately activated complement cascade leads to damage and subsequent build up of deposits in the retina in patients with glomerulonephritis, and are often confused with age-related macular degeneration in a patient far too young for the disease. On histopathology, these deposits are morphologically similar to the deposits in the kidney. There is PAS-positive material in the choroidal blood vessels and in Bruch's membrane over a thinned choroid. Interestingly, the deposits of two types of glomerulonephritis (membranous glomerulonephritis and post-streptococcal glomerulonephritis) have extensive similarity on histochemical, immunohistochemical, and ultrastructural evaluation in comparison to the drusen of age-related macular degeneration (Table 1). Despite the clinical similarity of glomerulopathy-associated drusen and drusen of AMD, AMD and renal disease do not have a high coincidence, and may reflect a more local activation of the complement cascade confined to the retina in AMD that is influenced both by genetics and the environment.[10 ,11]
Patients with glomerulopathy-associated drusen frequently remain asymptomatic. In a series of 23 patients with complement-mediated glomerulonephritis, nine patients and 17 eyes had retinal features related to the kidney disease but only five patients (22%) and six eyes (13%) had vision loss. Metamorphopsia may signal underlying choroidal neovascular membrane (CNVM), which develops in 10% of individuals. Similar to AMD, there are reports of vision loss due to retinal geographic atrophy. Vision loss may also indicate an associated central serous chorioretinopathy (CSCR), which may develop due to the concurrent steroid use and not the underlying kidney/retinal disease.[4 ,5]
On dilated fundus exam, the most common retinal finding in C3 glomerulopathy is basal laminar drusen. These drusen are often present on the first examination of the patient, but in some young adolescent patients the drusen may be absent.[4 ,13] These drusen are numerous, small, yellow lesions clustered in the temporal portion of the macula, and are symmetric between the two eyes.[4 ,13 ,14] The longer the patient has the disease, the greater the number and size of the drusen and the greater the risk for complications, independent of patient age.[5 ,13] In one series, all the patients with CNVM had the glomerulopathy for >15 years.
The differential diagnosis for findings seen in glomerulopathy-associated drusen includes age-related macular degeneration, pattern macular dystrophy, autosomal dominant radial drusen, North Carolina macular dystrophy, Sorsby macular dystrophy, cuticular drusen and C3 glomerulopathies.[10 ,15] Typically, the fundus appearance on dilated exam in the setting of renal disease is often very supportive of the diagnosis. Drusen in a typical distribution in a young patient with biopsy-proven C3 glomerulopathy is almost certainly due to the patient's underlying kidney disease.
Additional functional tests are often not performed nor required, but there are reports of abnormal functional tests in glomerulopathy-associated drusen. Electro-oculography (EOG) may have low Arden ratios with a normal electroretinography (ERG) as shown in a series of three patients with the typical fundus appearance. Mild visual field loss, color vision abnormalities on Farnsworth D-15 test, prolonged dark adaptation, and delayed, but normal amplitude ERGs were reported in another study.
Patients will often have urinalysis performed for hematuria and will show nephrotic range proteinuria and hematuria. In the later diagnostic workup, kidney biopsy is an important diagnostic tool, and C3 glomerulopathy patients will have C3 deposition in the glomerular basement membrane on immunofluorescence preparations. Other features on biopsy include variable light microscope appearance, electron microscopic appearance, and immunoglobulin deposition.
The most useful modality in diagnosis and monitoring of C3 glomerulopathy-associated drusen is optical coherence tomography (OCT). OCT can help visualize the basal laminar drusen and associated retinal pigment epithelium (RPE) detachments. Sometimes, fluorescein angiography (FA) is utilized and can show a greater number of lesions in the retina than seen on OCT. However, OCT is preferred due to its non-invasive modality.
A nephrologist should manage treatment of the kidney disease. Treatment of the disease is often aimed at anti-complement therapies, angiotensin converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB). Additional therapies may include lipid lowering agents, plasma therapy, and anti-cellular therapy. Even with treatment, renal function is variable.
The treatment of ocular disease complications from C3 glomerulopathy lacks strong evidence, and many treatment decisions originate from knowledge of the treatment of more common diseases like age-related macular degeneration. Photodynamic therapy (PDT) is often a mainstay of treatment for CNVM. However, the therapy is not used for juxtafoveal CNVM due to the potential vision loss. There have been case reports of the successful treatment with anti-vascular endothelial growth factor (VEGF) therapies ranibizumab and aflibercept.[4 ,6]
AREDS vitamins are often used in non-exudative AMD to prevent progression to neovascular AMD. However, no data regarding the use of these supplements in glomerulopathy-associated drusen is available. Due to the similarities between glomerulopathy-associated drusen and AMD in pathophysiology and natural history, some patients will elect to use these supplements, but caution should be advised due to their renal impairment and lack of verified treatment evidence.
Recommendations regarding visually asymptomatic patients are controversial with no agreement on the need for screening exams.[4 ,5] The renal disease does not correlate with the severity of retinal disease, and thus a threshold for eye exams cannot be made. Despite this, as with any patient, regular dilated exams should be performed to detect other eye diseases early.
EPIDEMIOLOGY AND ETIOLOGY
- Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, Braun TA, Mullins RF, Scheetz TE, Sheffield VC, Tucker BA. Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease. Ophthalmology 2017;124(9):1314-1331. https://www.ncbi.nlm.nih.gov/pubmed/28559085
- Sohn EH, Wang K, Thompson S, Riker MJ, Hoffmann JM, Stone EM, Mullins RF. Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related macular degeneration. Retina 2015;35(1):48-57. https://www.ncbi.nlm.nih.gov/pubmed/25077532
- Nester CM, Smith RJ. Diagnosis and treatment of C3 glomerulopathy. Clin Nephrol 2013;80(6):395-403. https://www.ncbi.nlm.nih.gov/pubmed/23993166
- Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Comparative Consecutive Series. Ophthalmology 2016;123(7):1588-1594. https://www.ncbi.nlm.nih.gov/pubmed/26996341
- McAvoy CE, Silvestri G. Retinal changes associated with type 2 glomerulonephritis. Eye (Lond) 2005;19(9):985-989. https://www.ncbi.nlm.nih.gov/pubmed/15375355
- McCullagh D, Silvestri G, Maxwell AP. Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab. BMJ Case Rep 2014;2014. https://www.ncbi.nlm.nih.gov/pubmed/24895384
- Online Mendelian Inheritance in Man, MIM Number:134370. Johns Hopkins University, Baltimore, MD. Edited 10/7/16: Available from: http://omim.org/entry/134370.
- Grassi MA, Folk JC, Scheetz TE, Taylor CM, Sheffield VC, Stone EM. Complement factor H polymorphism p.Tyr402His and cuticular Drusen. Arch Ophthalmol 2007;125(1):93-97. https://www.ncbi.nlm.nih.gov/pubmed/17210858
- Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 1989;73(4):297-302. https://www.ncbi.nlm.nih.gov/pubmed/2713310
- Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye (Lond) 2001;15(Pt 3):390-395. https://www.ncbi.nlm.nih.gov/pubmed/11450763
- Mullins RF, Warwick AN, Sohn EH, Lotery AJ. From compliment to insult: genetics of the complement system in physiology and disease in the human retina. Hum Mol Genet 2017;26(R1):R51-R57. https://www.ncbi.nlm.nih.gov/pubmed/28482029
- Savige J, Amos L, Ierino F, Mack HG, Symons RC, Hughes P, Nicholls K, Colville D. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet 2016;37(4):369-376. https://www.ncbi.nlm.nih.gov/pubmed/26915021
- Leys A, Vanrenterghem Y, Van Damme B, Snyers B, Pirson Y, Leys M. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol 1991;229(5):406-410. https://www.ncbi.nlm.nih.gov/pubmed/1937071
- D'Souza Y, Short CD, McLeod D, Bonshek RE. Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br J Ophthalmol 2008;92(7):950-953. https://www.ncbi.nlm.nih.gov/pubmed/18577648
- Sohn EH, Mullins RF, Stone EM. Macular Dystrophies. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, editors. Ryan's retina. Sixth edition ed: Elsevier; 2018; chapter Chapter 44; p. 953-996.
- O'Brien C, Duvall-Young J, Brown M, Short C, Bone M. Electrophysiology of type II mesangiocapillary glomerulonephritis with associated fundus abnormalities. Br J Ophthalmol 1993;77(12):778-780. https://www.ncbi.nlm.nih.gov/pubmed/8110672
- Kim RY, Faktorovich EG, Kuo CY, Olson JL. Retinal function abnormalities in membranoproliferative glomerulonephritis type II. Am J Ophthalmol 1997;123(5):619-628. https://www.ncbi.nlm.nih.gov/pubmed/9152067
- Batioglu F, Muftuoglu O, Atmaca L. Optical coherence tomography of fundus abnormalities associated with type II membranoproliferative glomerulonephritis. Retina 2003;23(2):261-262. https://www.ncbi.nlm.nih.gov/pubmed/12707615
Suggested Citation Format
Janson BJ, Oetting TA, Sohn EH. Early onset macular drusen and C3 glomerulopathy (formerly type II membranoproliferative glomerulonephritis-associated drusen). EyeRounds.org. posted October 9, 2017; Available from http://EyeRounds.org/cases/259-GA-Drusen.htm